Although in this study we focused on the KRAS and SMAD4 genetic mutations to categorize our CRC cell lines, [30–33, 56], we cannot disregard several other genes (e.g. BRAF, PIK3CA, c-MET) whose mutations can further impact the CRC patient disease outcome. This evidence concerns the gene MET and colorectal carcinoma.